No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
JAPAN — Pharmacosmos, a pharmaceutical company based in Denmark, has announced the release of its intravenous treatment for iron deficiency anemia, Monofer (ferric derisomaltose), in Japan. The launch follows the…
Read More
KENYA – The Ministry of Health is collaborating with Japanese engineers on a Vaccination Management System (VMS) that will include biometric technologies. This system aims to improve the survival rates…
Read More
JAPAN —Eisai has announced that its Alzheimer’s disease drug Leqembi (lecanemab), developed in partnership with Biogen, is expected to generate peak sales of JPY 1.2 trillion (US$7.4 billion) by the…
Read More
JAPAN — Takeda, a pharmaceutical company from Japan, has partnered with Hong Kong-based Hutchmed to gain commercial rights to the colorectal cancer drug fruquintinib outside of China for US$400 million,…
Read More
JAPAN — Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of the Nimbus Lakshmi program from Nimbus Therapeutics in a deal worth up to US$6 billion. Under…
Read More
JAPAN — Scientists from Nagoya University in Japan have developed a new device that detects a specific membrane protein in urine to determine if a patient has a brain tumor.…
Read More
JAPAN — The four biggest pharmaceutical companies in Japan, Astellas Pharma Inc., Eisai Co., Daiichi Sankyo Company, and Takeda Pharmaceutical have agreed to collaborate to reduce environmental burden in the…
Read More
SYRIA – The United Nations Children’s Fund (UNICEF) has received US$5.1 million in funding from the Government of Japan to scale up delivery of quality healthcare in the Syrian Arab…
Read More
JAPAN — Takeda Pharmaceutical has agreed to pay up to US$6 billion (813 billion) for an experimental immune therapy developed by Nimbus Therapeutics, as part of the Japanese pharmaceutical company’s…
Read More
JAPAN — The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adults with HER2-positive unresectable or recurrent breast cancer.…
Read More